Cencora, Inc. $COR Stake Trimmed by Boston Partners

Boston Partners reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,196,536 shares of the company’s stock after selling 312,629 shares during the period. Cencora comprises 1.5% of Boston Partners’ investment portfolio, making the stock its 2nd largest holding. Boston Partners’ holdings in Cencora were worth $1,418,420,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in COR. Oakworth Capital Inc. purchased a new stake in Cencora during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC purchased a new stake in Cencora during the 4th quarter worth approximately $27,000. Archer Investment Corp increased its stake in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the period. IAG Wealth Partners LLC purchased a new stake in Cencora during the 3rd quarter worth approximately $30,000. Finally, Caitlin John LLC purchased a new stake in shares of Cencora during the third quarter worth approximately $31,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on COR shares. Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Robert W. Baird cut their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Barclays cut their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday. William Blair started coverage on shares of Cencora in a research note on Tuesday, April 28th. They set a “market perform” rating on the stock. Finally, UBS Group upped their target price on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Twelve analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $374.00.

Cencora Trading Up 0.0%

COR opened at $281.56 on Friday. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The company has a market cap of $54.78 billion, a P/E ratio of 21.59, a PEG ratio of 1.52 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The business’s 50-day simple moving average is $289.22 and its 200-day simple moving average is $327.63.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the company posted $4.42 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts expect that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s dividend payout ratio is presently 18.40%.

Cencora declared that its Board of Directors has initiated a stock repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.